Oramed Pharmaceuticals Inc. (ORMP) — Analysis Summary
Oramed Pharmaceuticals Inc. (ORMP) has a market cap of $180.12M with year-over-year revenue growth of +49.3%. Net margin stands at 3202.5%. The stock trades at a P/E ratio of 1.0.
Key Takeaways
- Revenue changed +49.3% year-over-year
- Net margin of 3202.5%
- P/E ratio of 1.0
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ORMP posted revenue growth of +49.3% and trades at a P/E of 1.0.
Oramed Pharmaceuticals Inc. (ORMP)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -726.2% — severe operating losses
The latest filing shows negative free cash flow.
Operating cash flow is negative while net income remains positive.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
13
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.